Preparation and Evaluation of Sildenafil Loaded with Pegylated Liposomes used for Hypertension

Abstract

PEGylated liposomes were successfully synthesized using the thin film hydration method to enhance the pharmacokinetic profile of sildenafil. The developed liposomal formulations exhibited optimal physicochemical properties, including desirable particle size, low polydispersity index (PDI), favorable zeta potential, and high encapsulation efficiency. Among the various formulations, SL-3 demonstrated superior performance, showing enhanced vasorelaxation activity and a significant reduction in mean systolic arterial pressure compared to conventional sildenafil and the marketed formulation Revetio®. The PEGylated liposomes provided sustained drug release, improved bioavailability, reduced dosing frequency, and enhanced stability, contributing to better patient compliance with minimal adverse effects. The nanoscale size of these liposomes supports their suitability for parenteral administration and prolonged therapeutic action. While the results are promising, further investigations are warranted to validate their efficacy under various physiological and pathological conditions.